Cargando…

Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs

Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Roda, Giulia, Porru, Emanuele, Katsanos, Konstantinos, Skamnelos, Alexandros, Kyriakidi, Kallirroi, Fiorino, Gionata, Christodoulou, Dimitrios, Danese, Silvio, Roda, Aldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721523/
https://www.ncbi.nlm.nih.gov/pubmed/31382518
http://dx.doi.org/10.3390/cells8080817
_version_ 1783448362791469056
author Roda, Giulia
Porru, Emanuele
Katsanos, Konstantinos
Skamnelos, Alexandros
Kyriakidi, Kallirroi
Fiorino, Gionata
Christodoulou, Dimitrios
Danese, Silvio
Roda, Aldo
author_facet Roda, Giulia
Porru, Emanuele
Katsanos, Konstantinos
Skamnelos, Alexandros
Kyriakidi, Kallirroi
Fiorino, Gionata
Christodoulou, Dimitrios
Danese, Silvio
Roda, Aldo
author_sort Roda, Giulia
collection PubMed
description Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process.
format Online
Article
Text
id pubmed-6721523
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67215232019-09-10 Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs Roda, Giulia Porru, Emanuele Katsanos, Konstantinos Skamnelos, Alexandros Kyriakidi, Kallirroi Fiorino, Gionata Christodoulou, Dimitrios Danese, Silvio Roda, Aldo Cells Article Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process. MDPI 2019-08-02 /pmc/articles/PMC6721523/ /pubmed/31382518 http://dx.doi.org/10.3390/cells8080817 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roda, Giulia
Porru, Emanuele
Katsanos, Konstantinos
Skamnelos, Alexandros
Kyriakidi, Kallirroi
Fiorino, Gionata
Christodoulou, Dimitrios
Danese, Silvio
Roda, Aldo
Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title_full Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title_fullStr Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title_full_unstemmed Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title_short Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
title_sort serum bile acids profiling in inflammatory bowel disease patients treated with anti-tnfs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721523/
https://www.ncbi.nlm.nih.gov/pubmed/31382518
http://dx.doi.org/10.3390/cells8080817
work_keys_str_mv AT rodagiulia serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT porruemanuele serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT katsanoskonstantinos serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT skamnelosalexandros serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT kyriakidikallirroi serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT fiorinogionata serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT christodouloudimitrios serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT danesesilvio serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs
AT rodaaldo serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs